A quick look back at top stories.

Biopharma money raised to-date and by month in 2021, including public, private and other financings.

The top 10 biopharma stock gainers and losers for the week.

Entering 2021 with a strong reputation following a year of intense pandemic-related research, the biopharma industry is drawing enormous investor interest as financings continue to shoot skyward.

According to an analysis conducted by BioWorld of the 2020 financial reports filed by public biopharmaceutical companies with market caps greater than $1 billion, and excluding big pharma companies, the amount that was invested in research and development (R&D) during the year increased by 23% compared to the same period last year.

NEW DELHI – Significant disruptions to supplies of active pharmaceutical ingredients (APIs) from China caused by the COVID-19 pandemic have led India to fundamentally rethink its supply chains and the structure of its pharmaceutical industry, according to industry executives and consultants.